The Influence of IL-12 and/or Epo on the Number of Platelets and the Hemoglobin Concentration in Peripheral Blood
| In Vivo Treatment . | Platelets (×109/mL) . | Hemoglobin (g/L) . |
|---|---|---|
| 0.1% BSA-PBS | 1004.5 ± 195.4 | 189.5 ± 25.0 |
| Epo | 853.6 ± 312.5 | 216.0 ± 21.9 |
| IL-12 | 612.9 ± 98.9-150 | 156.1 ± 8.5-150 |
| IL-12 + Epo | 887.6 ± 193.9-151 | 205.5 ± 29.3-151 |
| In Vivo Treatment . | Platelets (×109/mL) . | Hemoglobin (g/L) . |
|---|---|---|
| 0.1% BSA-PBS | 1004.5 ± 195.4 | 189.5 ± 25.0 |
| Epo | 853.6 ± 312.5 | 216.0 ± 21.9 |
| IL-12 | 612.9 ± 98.9-150 | 156.1 ± 8.5-150 |
| IL-12 + Epo | 887.6 ± 193.9-151 | 205.5 ± 29.3-151 |
Five to seven 9-week-old B6D2F1 melanoma-bearing male mice were used per group. Mice were treated intraperitoneally with IL-12 (0.1 μg/injection) and/or Epo (20 U/injection given twice daily) or with 0.1% BSA-PBS for 7 consecutive days. Blood was collected on day 8, 12 hours after the last injection, and analyzed using Sysmex-820 cell counter (Sysmex, Kyoto, Japan) adjusted to the analysis of rodent cells. Results represent the mean ± SD.
P < .01 versus controls.
P < .01 versus IL-12–treated mice (Student'st-test).